RxDoctor Payments Data

Renjana Mony, MD

Family Medicine · Dallas, TXNPI 1255580528

Payments from drug & device makers

$350in general payments, 2019–2025

Across 17 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$135
  • Amgen$66
  • AstraZeneca$37
  • Boehringer Ingelheim$31
  • Pfizer$19
  • Eisai Inc.$19
  • plus $43 from 3 others

What the payments were for

  • Food & beverage$350100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$350 in reported general payments places this provider in the 45th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$27,510
Medicare patients
69
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin57$72,365
EliquisApixaban58$61,173
OzempicSemaglutide60$56,824
TrulicityDulaglutide32$47,151
MounjaroTirzepatide41$40,978
FarxigaDapagliflozin Propanediol35$38,157
LinzessLinaclotide20$18,642
XareltoRivaroxaban17$18,501
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$14,068
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,961
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,595
Gabapentin174$3,153
Humulin 70-30Insulin Nph Hum/Reg Insulin Hm13$3,095
Nano 2nd Gen Pen NeedlePen Needle, Diabetic21$2,958
ValacyclovirValacyclovir Hcl19$2,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$31$72,36557 claims
PfizerEliquis$19$61,17358 claims
AstraZenecaFarxiga$37$38,15735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →